Similarity Score |
Similarity Level |
Drug ID |
Developmental Stage |
0.8632 |
High Similarity |
NPD4749 |
Approved |
0.8417 |
Intermediate Similarity |
NPD6917 |
Clinical (unspecified phase) |
0.8361 |
Intermediate Similarity |
NPD3027 |
Phase 3 |
0.8318 |
Intermediate Similarity |
NPD940 |
Approved |
0.8318 |
Intermediate Similarity |
NPD846 |
Approved |
0.8305 |
Intermediate Similarity |
NPD1610 |
Phase 2 |
0.8293 |
Intermediate Similarity |
NPD6410 |
Clinical (unspecified phase) |
0.8288 |
Intermediate Similarity |
NPD4750 |
Phase 3 |
0.8276 |
Intermediate Similarity |
NPD1548 |
Phase 1 |
0.8211 |
Intermediate Similarity |
NPD4625 |
Phase 3 |
0.8142 |
Intermediate Similarity |
NPD228 |
Approved |
0.813 |
Intermediate Similarity |
NPD4908 |
Phase 1 |
0.8056 |
Intermediate Similarity |
NPD1242 |
Phase 1 |
0.8049 |
Intermediate Similarity |
NPD1530 |
Clinical (unspecified phase) |
0.8017 |
Intermediate Similarity |
NPD6671 |
Approved |
0.8 |
Intermediate Similarity |
NPD4907 |
Clinical (unspecified phase) |
0.8 |
Intermediate Similarity |
NPD422 |
Phase 1 |
0.7984 |
Intermediate Similarity |
NPD1529 |
Clinical (unspecified phase) |
0.7874 |
Intermediate Similarity |
NPD1612 |
Clinical (unspecified phase) |
0.7874 |
Intermediate Similarity |
NPD1613 |
Approved |
0.785 |
Intermediate Similarity |
NPD844 |
Approved |
0.7724 |
Intermediate Similarity |
NPD2983 |
Phase 2 |
0.7724 |
Intermediate Similarity |
NPD2982 |
Phase 2 |
0.7719 |
Intermediate Similarity |
NPD2684 |
Approved |
0.771 |
Intermediate Similarity |
NPD6099 |
Approved |
0.771 |
Intermediate Similarity |
NPD6100 |
Approved |
0.7699 |
Intermediate Similarity |
NPD968 |
Approved |
0.7661 |
Intermediate Similarity |
NPD6696 |
Suspended |
0.7642 |
Intermediate Similarity |
NPD2981 |
Phase 2 |
0.7632 |
Intermediate Similarity |
NPD290 |
Approved |
0.7619 |
Intermediate Similarity |
NPD3018 |
Phase 2 |
0.7619 |
Intermediate Similarity |
NPD2861 |
Phase 2 |
0.7615 |
Intermediate Similarity |
NPD288 |
Approved |
0.7597 |
Intermediate Similarity |
NPD1240 |
Approved |
0.7593 |
Intermediate Similarity |
NPD1432 |
Clinical (unspecified phase) |
0.7581 |
Intermediate Similarity |
NPD3600 |
Clinical (unspecified phase) |
0.7568 |
Intermediate Similarity |
NPD289 |
Clinical (unspecified phase) |
0.7542 |
Intermediate Similarity |
NPD5283 |
Phase 1 |
0.7541 |
Intermediate Similarity |
NPD4626 |
Approved |
0.7541 |
Intermediate Similarity |
NPD1778 |
Approved |
0.7523 |
Intermediate Similarity |
NPD2860 |
Approved |
0.7523 |
Intermediate Similarity |
NPD2859 |
Approved |
0.75 |
Intermediate Similarity |
NPD1608 |
Approved |
0.75 |
Intermediate Similarity |
NPD2230 |
Approved |
0.75 |
Intermediate Similarity |
NPD2232 |
Approved |
0.75 |
Intermediate Similarity |
NPD2233 |
Approved |
0.7481 |
Intermediate Similarity |
NPD6398 |
Clinical (unspecified phase) |
0.7481 |
Intermediate Similarity |
NPD1607 |
Approved |
0.7477 |
Intermediate Similarity |
NPD3020 |
Approved |
0.7463 |
Intermediate Similarity |
NPD970 |
Clinical (unspecified phase) |
0.7462 |
Intermediate Similarity |
NPD2238 |
Phase 2 |
0.7458 |
Intermediate Similarity |
NPD821 |
Approved |
0.7458 |
Intermediate Similarity |
NPD7843 |
Approved |
0.7453 |
Intermediate Similarity |
NPD9295 |
Approved |
0.7442 |
Intermediate Similarity |
NPD6859 |
Clinical (unspecified phase) |
0.7431 |
Intermediate Similarity |
NPD2933 |
Approved |
0.7431 |
Intermediate Similarity |
NPD2934 |
Approved |
0.7419 |
Intermediate Similarity |
NPD1091 |
Approved |
0.7417 |
Intermediate Similarity |
NPD7157 |
Approved |
0.7402 |
Intermediate Similarity |
NPD6584 |
Phase 3 |
0.7368 |
Intermediate Similarity |
NPD1510 |
Phase 2 |
0.7353 |
Intermediate Similarity |
NPD9093 |
Approved |
0.735 |
Intermediate Similarity |
NPD5451 |
Approved |
0.7339 |
Intermediate Similarity |
NPD3496 |
Discontinued |
0.7339 |
Intermediate Similarity |
NPD845 |
Approved |
0.7317 |
Intermediate Similarity |
NPD1357 |
Approved |
0.7293 |
Intermediate Similarity |
NPD6111 |
Discontinued |
0.7287 |
Intermediate Similarity |
NPD596 |
Approved |
0.7287 |
Intermediate Similarity |
NPD600 |
Approved |
0.7282 |
Intermediate Similarity |
NPD9089 |
Approved |
0.728 |
Intermediate Similarity |
NPD3705 |
Approved |
0.7273 |
Intermediate Similarity |
NPD709 |
Approved |
0.7258 |
Intermediate Similarity |
NPD2667 |
Approved |
0.7258 |
Intermediate Similarity |
NPD2668 |
Approved |
0.7258 |
Intermediate Similarity |
NPD17 |
Approved |
0.725 |
Intermediate Similarity |
NPD1398 |
Phase 1 |
0.7241 |
Intermediate Similarity |
NPD1445 |
Approved |
0.7241 |
Intermediate Similarity |
NPD1444 |
Approved |
0.7238 |
Intermediate Similarity |
NPD111 |
Approved |
0.7226 |
Intermediate Similarity |
NPD3892 |
Phase 2 |
0.7222 |
Intermediate Similarity |
NPD2231 |
Phase 2 |
0.7222 |
Intermediate Similarity |
NPD2235 |
Phase 2 |
0.7207 |
Intermediate Similarity |
NPD1809 |
Phase 2 |
0.7203 |
Intermediate Similarity |
NPD3022 |
Approved |
0.7203 |
Intermediate Similarity |
NPD3021 |
Approved |
0.7177 |
Intermediate Similarity |
NPD1651 |
Approved |
0.7177 |
Intermediate Similarity |
NPD5691 |
Approved |
0.7174 |
Intermediate Similarity |
NPD2219 |
Phase 1 |
0.7167 |
Intermediate Similarity |
NPD1138 |
Approved |
0.7165 |
Intermediate Similarity |
NPD6582 |
Phase 2 |
0.7165 |
Intermediate Similarity |
NPD6583 |
Phase 3 |
0.7165 |
Intermediate Similarity |
NPD1669 |
Approved |
0.7165 |
Intermediate Similarity |
NPD4379 |
Clinical (unspecified phase) |
0.7143 |
Intermediate Similarity |
NPD4378 |
Clinical (unspecified phase) |
0.7143 |
Intermediate Similarity |
NPD7447 |
Phase 1 |
0.7143 |
Intermediate Similarity |
NPD3157 |
Approved |
0.7143 |
Intermediate Similarity |
NPD5124 |
Phase 1 |
0.7143 |
Intermediate Similarity |
NPD5123 |
Clinical (unspecified phase) |
0.7143 |
Intermediate Similarity |
NPD3158 |
Phase 1 |
0.7143 |
Intermediate Similarity |
NPD230 |
Phase 1 |
0.7132 |
Intermediate Similarity |
NPD602 |
Approved |
0.7132 |
Intermediate Similarity |
NPD1550 |
Clinical (unspecified phase) |
0.7132 |
Intermediate Similarity |
NPD1552 |
Clinical (unspecified phase) |
0.7132 |
Intermediate Similarity |
NPD858 |
Approved |
0.7132 |
Intermediate Similarity |
NPD859 |
Approved |
0.7132 |
Intermediate Similarity |
NPD4624 |
Approved |
0.7132 |
Intermediate Similarity |
NPD599 |
Approved |
0.7121 |
Intermediate Similarity |
NPD839 |
Approved |
0.7121 |
Intermediate Similarity |
NPD840 |
Approved |
0.7117 |
Intermediate Similarity |
NPD9296 |
Approved |
0.7109 |
Intermediate Similarity |
NPD1283 |
Approved |
0.7101 |
Intermediate Similarity |
NPD1878 |
Clinical (unspecified phase) |
0.7094 |
Intermediate Similarity |
NPD3134 |
Approved |
0.709 |
Intermediate Similarity |
NPD4097 |
Suspended |
0.709 |
Intermediate Similarity |
NPD1772 |
Clinical (unspecified phase) |
0.7083 |
Intermediate Similarity |
NPD1137 |
Approved |
0.7083 |
Intermediate Similarity |
NPD1139 |
Approved |
0.708 |
Intermediate Similarity |
NPD1549 |
Phase 2 |
0.7077 |
Intermediate Similarity |
NPD1712 |
Approved |
0.7073 |
Intermediate Similarity |
NPD7340 |
Approved |
0.7071 |
Intermediate Similarity |
NPD7213 |
Phase 3 |
0.7071 |
Intermediate Similarity |
NPD7212 |
Phase 2 |
0.7068 |
Intermediate Similarity |
NPD4060 |
Phase 1 |
0.7068 |
Intermediate Similarity |
NPD3620 |
Phase 2 |
0.7068 |
Intermediate Similarity |
NPD3619 |
Clinical (unspecified phase) |
0.7068 |
Intermediate Similarity |
NPD1558 |
Phase 1 |
0.7063 |
Intermediate Similarity |
NPD3847 |
Discontinued |
0.7059 |
Intermediate Similarity |
NPD2935 |
Discontinued |
0.7059 |
Intermediate Similarity |
NPD1551 |
Phase 2 |
0.7059 |
Intermediate Similarity |
NPD1792 |
Phase 2 |
0.7054 |
Intermediate Similarity |
NPD2797 |
Approved |
0.7034 |
Intermediate Similarity |
NPD1358 |
Approved |
0.7025 |
Intermediate Similarity |
NPD5535 |
Approved |
0.7021 |
Intermediate Similarity |
NPD2532 |
Approved |
0.7021 |
Intermediate Similarity |
NPD2533 |
Approved |
0.7021 |
Intermediate Similarity |
NPD2534 |
Approved |
0.7007 |
Intermediate Similarity |
NPD3540 |
Phase 1 |
0.7 |
Intermediate Similarity |
NPD3691 |
Phase 2 |
0.7 |
Intermediate Similarity |
NPD558 |
Phase 2 |
0.7 |
Intermediate Similarity |
NPD3690 |
Phase 2 |
0.6992 |
Remote Similarity |
NPD2674 |
Phase 3 |
0.6986 |
Remote Similarity |
NPD2393 |
Clinical (unspecified phase) |
0.6983 |
Remote Similarity |
NPD9500 |
Approved |
0.6978 |
Remote Similarity |
NPD3750 |
Approved |
0.6977 |
Remote Similarity |
NPD8651 |
Approved |
0.696 |
Remote Similarity |
NPD9545 |
Approved |
0.695 |
Remote Similarity |
NPD1511 |
Approved |
0.695 |
Remote Similarity |
NPD4357 |
Discontinued |
0.6944 |
Remote Similarity |
NPD4005 |
Discontinued |
0.6935 |
Remote Similarity |
NPD9493 |
Approved |
0.6934 |
Remote Similarity |
NPD2796 |
Approved |
0.6934 |
Remote Similarity |
NPD3539 |
Phase 1 |
0.6929 |
Remote Similarity |
NPD5307 |
Clinical (unspecified phase) |
0.6918 |
Remote Similarity |
NPD1934 |
Approved |
0.6918 |
Remote Similarity |
NPD37 |
Approved |
0.6912 |
Remote Similarity |
NPD2200 |
Suspended |
0.6906 |
Remote Similarity |
NPD1652 |
Phase 2 |
0.6906 |
Remote Similarity |
NPD5698 |
Clinical (unspecified phase) |
0.6905 |
Remote Similarity |
NPD5585 |
Approved |
0.6899 |
Remote Similarity |
NPD5327 |
Phase 3 |
0.6899 |
Remote Similarity |
NPD3685 |
Discontinued |
0.6899 |
Remote Similarity |
NPD3676 |
Clinical (unspecified phase) |
0.6894 |
Remote Similarity |
NPD1008 |
Clinical (unspecified phase) |
0.6889 |
Remote Similarity |
NPD5735 |
Approved |
0.6885 |
Remote Similarity |
NPD7635 |
Approved |
0.6881 |
Remote Similarity |
NPD9094 |
Approved |
0.688 |
Remote Similarity |
NPD5536 |
Phase 2 |
0.6879 |
Remote Similarity |
NPD7124 |
Phase 2 |
0.6875 |
Remote Similarity |
NPD776 |
Approved |
0.6875 |
Remote Similarity |
NPD1653 |
Approved |
0.6875 |
Remote Similarity |
NPD1281 |
Approved |
0.6871 |
Remote Similarity |
NPD2801 |
Approved |
0.6861 |
Remote Similarity |
NPD7033 |
Discontinued |
0.6861 |
Remote Similarity |
NPD5788 |
Clinical (unspecified phase) |
0.6855 |
Remote Similarity |
NPD2557 |
Approved |
0.6853 |
Remote Similarity |
NPD1512 |
Approved |
0.685 |
Remote Similarity |
NPD5846 |
Approved |
0.685 |
Remote Similarity |
NPD6516 |
Phase 2 |
0.6847 |
Remote Similarity |
NPD9365 |
Approved |
0.6846 |
Remote Similarity |
NPD3225 |
Approved |
0.6842 |
Remote Similarity |
NPD7095 |
Approved |
0.6838 |
Remote Similarity |
NPD6653 |
Approved |
0.6838 |
Remote Similarity |
NPD6651 |
Approved |
0.6829 |
Remote Similarity |
NPD1241 |
Discontinued |
0.6825 |
Remote Similarity |
NPD1182 |
Approved |
0.6825 |
Remote Similarity |
NPD3091 |
Approved |
0.6822 |
Remote Similarity |
NPD9717 |
Approved |
0.6818 |
Remote Similarity |
NPD9494 |
Approved |
0.6815 |
Remote Similarity |
NPD4140 |
Approved |
0.68 |
Remote Similarity |
NPD3596 |
Phase 2 |
0.68 |
Remote Similarity |
NPD6234 |
Discontinued |
0.6791 |
Remote Similarity |
NPD3268 |
Approved |
0.6791 |
Remote Similarity |
NPD1296 |
Phase 2 |
0.6791 |
Remote Similarity |
NPD3145 |
Approved |
0.6791 |
Remote Similarity |
NPD3144 |
Approved |
0.6791 |
Remote Similarity |
NPD1039 |
Discontinued |
0.6788 |
Remote Similarity |
NPD4537 |
Clinical (unspecified phase) |
0.6788 |
Remote Similarity |
NPD4536 |
Approved |
0.6788 |
Remote Similarity |
NPD4538 |
Approved |
0.6786
|
Remote Similarity |
NPD3060 |
Approved |